Shanghai Pharmaceuticals (601607) H2 2024 earnings summary

Executive summary

• Achieved revenue of RMB 275.25 billion in 2024, up 5.75% year-over-year, with net profit attributable to shareholders rising 20.82% to RMB 4.55 billion.

• Maintained position in the Fortune Global 500, ranking 411th, and recognized among global top 50 pharmaceutical companies.

• R&D investment reached RMB 2.82 billion, with 54 new drug pipelines in clinical or application stages.

• Cash flow from operations increased 11.39% to RMB 5.83 billion, supporting high-quality growth.

Financial highlights

• Revenue: RMB 275.25 billion, up 5.75% year-over-year; net profit: RMB 4.55 billion, up 20.82%.

• Gross margin for industrial segment: 59.21%; distribution: 5.94%; retail: 12.84%.

• Basic and diluted EPS: RMB 1.23, up 20.59% year-over-year.

• Net assets attributable to shareholders: RMB 71.68 billion, up 4.60% year-over-year.

• Operating cash flow: RMB 5.83 billion, up 11.39% year-over-year.

Outlook and guidance

• Strategic focus on innovation, digital supply chain, and international expansion.

• 2025 plans include strengthening core business, expanding R&D, and leveraging AI and advanced technologies.

• Continued risk management in response to global economic and policy uncertainties.